Seizure-inducing effects of antiepileptic drugs: A review

Acta Neurologica Scandinavica

Volumn 94, Issue 6, 1996, Pages 367-377

  Bauer, J ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Epilepsy; Pharmacotherapy; Seizure inducing effects

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

EPILEPSY; FOCAL EPILEPSY; HUMAN; LENNOX GASTAUT SYNDROME; MYOCLONUS SEIZURE; REVIEW; SEIZURE; TONIC CLONIC SEIZURE; WEST SYNDROME;

EID: 0030444347     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb00047.x     Document Type: Review

References (146)

1. DEAN JC, PENRY JK. Discontinuation of antiepileptic drugs. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 201-209.
2. ZACCARA G, MUSCAS GC, MESSORI A. Clinical features, pathogenesis, and management of drug-induced seizures. Drug Safety 1990: 5: 109-151.
3. TROUPIN AS, OJEMANN LM. Paradoxical intoxication - a complication of anticonvulsant administration. Epilepsia 1975: 16: 753-758.
4. LERMAN P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986: 27: 706-710.
5. PLAA GL, WILLMORE LJ. General Principles. Toxicology. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 51-60.
6. GRAM L, DULAC O. Antiepileptic drug-induced worsening of seizures in adults and children (abstract). Epilepsia 1995: 36(Suppl 3): S57.
7. GRAM L. How do you treat epilepsy. In: DAM M, ed. A practical approach to epilepsy. New York: Pergamon Press, 1991: 105-135.
8. MATTSON RH. Selection of antiepileptic drug therapy. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 137-148.
9. DICHTER MA. Old and new mechanisms of antiepileptic drug actions. In: FRENCH JA, DICHTER MA, LEPPIK IE, eds. New antiepileptic drug development: preclinical and clinical aspects (Epilepsy Res Suppl 10). Amsterdam; Elsevier, 1993: 9-17.
10. BOURGEOIS BFD. Pharmacologic intervention and treatment of childhood seizure disorders: relative efficacy and safety of antiepileptic drugs. Epilepsia 1994: 35(Suppl 2): S18-S23.
11. LORTIE A, CHIRON C, MUMFORD J, DULAC O. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993: 43(Suppl 5): S24-S27.
12. PELLOCK JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994: 44(Suppl 8): S29-S35.
13. NEUFELD MY. Exacerbation of focal seizures due to carbamazepine treatment in an adult patient. Clin Neuropharmacol 1993: 16: 359-361.
14. HOLMES GL. Carbamazepine toxicity. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 567-579.
15. JOHNSEN SD, TARBY TJ, SIDELL AD. Carbamazepine-induced seizures. Ann Neurol 1984: 16: 392-393.
16. DHUNA A, PASCUAL-LEONE A, TALWAR D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991: 32: 275-278.
17. HORN CS, ATER SB, HURST DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 1986: 2: 340-345.
18. SNEAD OC, HORSEY LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985: 313: 916-921.
19. SO EL, RUGGLES KH, CASCINO GD, AHMANN PA, WEATHERFORD KW. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 1994: 35: 743-746.
20. SCHOEMAN JF, ELYAS AA, BRETT EM, LASCELLES PT. Correlation between plasma carbamazepine 10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol 1984: 24: 756-764.
21. BLUME WT, PILLAY N. Electrographic and clinical correlates of secondary bilateral synchrony. Epilepsia 1985: 26: 636-641.
22. PAZZAGLLA P, D'ALLESANDRO R, AMBROSETTO G, LUGARESI E. Drop attacks: an omnious change in the evolution of partial epilepsy. Neurology 1985: 35: 1725-1730.
23. RODIN EA, RIM CS, RENNICK PM. The effects of carbamazepine in patients with psychomotor epilepsy: results of a double blind study. Epilepsia 1974: 15: 547-561.
24. GRANT SM, HEEL RC. Vigabatrin. Drugs 1991: 41: 889-926.
25. REYNOLDS EH. Vigabatrin, rational treatment for chronic epilepsy. Br Med J 1990: 300: 277-278.
26. ROGERS D, BIRD J, EAMES P. Complex partial status after starting vigabatrin. Seizure 1993: 2: 155-156.
27. DE KROM MC, VERDUIN N, VISSER E, KLEIJER M, SCHOLTES F, DE GROEN JH. Status epilepticus during vigabatrin treatment: a report of three cases. Seizure 1995: 4: 159-162.
28. ARZIMANOGLOU A. Vigabatrin and complex partial status. Seizure 1994: 3: 79-80.
29. FISHER RS, KERRIGAN JF III. Vigabatrin. Toxicity. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 931-939.
30. LEVY LL, FENICHEL GM. Diphenylhydantoin activated seizures. Neurology 1965: 15: 716-722.
31. SHUPER A, VINING EPG. Photosensitive complex partial seizures aggravated by phenytoin. Pediatr Neurol 1991: 7: 471-472.
32. MELDRUM BS. Photosensitive epilepsy in Papio papio as a model for drug studies. In: COBB WA, VAN DUIJN H, eds. Contemporary clinical neurophysiology. Amsterdam: Elsevier, 1978: 317-322.
33. GOA KL, SORKIN EM. Gabapentin. Drugs 1993: 46: 409-427.
34. KRÄMER G. Gabapentin. Aktuel Neurol 1995: 22: 114-117.
35. ®): ein neues Antiepileptikum zur Zusatzbehandlung bislang therapieresistenter Epilepsien. Aktuel Neurol 1993: 20: 111-122.
36. GIBBS J, APPLETON RE, ROSENBLOOM L et al. Lamotrigine for intractable childhood epilepsy: a preliminary communication. Dev Med Child Neurol 1992: 34: 369-371.
37. SCHMIDT D. Benzodiazepines. Diazepam. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 705-724.
38. WILDER BJ, BRUNI J. Barbiturates: Phenobarbital, mephobarbital and metharbital. In: WILDER BJ, BRUNI J, eds. Seizure disorders: a pharmacological approach to treatment. New York: Raven Prss, 1981: 47-60.
39. JEAVONS PM, CLARK JE, MAHESHWARI MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate. Dev Med Child Neurol 1977: 19: 9-25.
40. LENNOX WG. Epilepsy and related disorders. Boston: Little Brown & Co, 1960.
41. LIVINGSTON S. Drug therapy for epilepsy. Springfield, Ill: Charles C Thomas, 1966.
42. TODOROV AB, LENN NJ, GABOR AJ. Exacerbation of generalized non-convulsive seizures with ethosuximide therapy. Arch Neurol 1978: 35: 389-391.
43. FRIEDEL B, LEMPP R. Grand-mal Provokation bei der Behandlung kindlicher Petit-mal mit Oxazolidinen oder Succinimiden und ihre therapeutischen Konsequenzen. Z Kinderheild 1962: 87: 42-51.
44. DULAC O, N'GUYEN T. The Lennox-Gastaut syndrome. Epilepsia 1993: 34(Suppl 7): S7-S17.
45. PRIOR PF, MACLAINE GN, SCOTT DF, LAURANCE BM. Tonic Status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia 1972: 13: 467-472.
46. BITTENCOURT PRM, RICHENS A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981: 22: 129-134.
47. MARTIN D. Intravenous nitrazepam in the treatment of epilepsy. Neuropädiatrie 1970: 2: 27-37.
48. ALVAREZ N, HARTFORD E, DOUBT C. Epileptic seizures induced by clonazepam. Clin Electroencephal 1981: 12: 57-65.
49. MUTOH K, OKUNO T, MITSUYOSHI I, HAYAKAWA T, HAMADA Y, MIKAWA H. Induction of tonic spasms by carbamazepine: observations on 2 infants. Jpn J Psychiatry Neurol 1993: 47: 304-305.
50. AICARDIE J, CHEVRIE JJ. Atypical benign partial epilepsy of children. Dev Med Child Neurol 1982: 24: 281-282.
51. SANDER JWAS, HART YM, PATSALOS PN, DUNCAN JS, SHORVON SD. Lamotrigine and generalized seizures (abstract). Epilepsia 1991: 32(Suppl 1): 59.
52. VALLARTA JM, BELL DB, REICHERT A. Progressive encephalopathy due to chronic hydantoin intoxication. Am J Dis Child 1974: 128: 27-34.
53. BAUER J, ELGER CE. Die akute Valproinsäure-Enzephalopathie. Aktuel Neurol 1993: 20: 16-21.
54. PAKALNIS A, DRAKE ME, DENIO L. Valproate-associated encephalopathy. J Epilepsy 1989: 2: 41-44.
55. RANGEL RJ, WARNER JJ, WILDER BJ. Valproic acid encephalopathy. J Epilepsy 1988: 1: 197-202.
56. JONES GL, MATSUO F, BARINGER JR, et al. Valproic acid-associated encephalopathy. West J Med 1990: 153: 199-202.
57. TARTARA A, MANNI R. Sodium valproate "encephalopathy": report of three cases with generalized epilepsy. Ital J Neurol Sci 1985: 6: 93-95.
58. DUCHE B, LOUISET P, DEMOTES-MAINARD J, LOISEAU P. Enephalopathie subaigue-Reaction idiosyncrasique a la carbamazepine? Rev Neurol 1987: 143: 211-213.
59. CALLAHAN DJ, NOETZEL MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology 1992: 42: 2198-2201.
60. SMITH CR. Encephalomyelopathy as an idiosyncratic reaction to carbamazepine: a case report. Neurology 1991: 41: 760-761.
61. NEUMANN B, STEINHOFF BJ. Die Carbamazepin-Enzephalopathie: eine seltene Nebenwirkung. Aktuel Neurol 1994: 21: 191-194.
62. MEISTRUP-LARSEN KI, HERMANN S, PERMIN H. Chronic dephenylhydantoin encephalopathy in mentally retarded children and adolescents with severe epilepsy. Acta Neurol Scand 1979: 60: 50-555.
63. SÄLKE-KELLERMANN A, BAIER H, RAMBECK B, BOENIGK HE, WOLF P. Acute encephalopathy with vigabatrin (letter). Lancet 1993: 342: 185.
64. SACKELLARES JC, LEE SI, DREIFUSS FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979: 20: 697-703.
65. MARESCAUX C, WARTER JM, MICHELETTI G, RUMBACH L, COQUILLAT G, KURTZ D. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982: 23: 297-305.
66. STEINHOFF BJ, STODIECK SRG, PAULUS W. Positiver Effekt von Flumazenil bei Valproat-"Enzephalopathie" unter dem Bild eines komplex-partiellen Status epilepticus. In: SCHEFFNER D, ed. Epilepsie 90. Reinbek: Einhorn Presse Verlag, 1991: 219-227.
67. BRODGEN RN, GOA KL. Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use. Drugs 1988: 35: 448-467.
68. BATSHAW ML, BRUSILOW SW. Valproate-induced hyperammonaemia. Ann Neurol 1982: 11: 319-321.
69. COULTER DL, ALLEN RJ. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy (letter). Lancet 1980: 1: 1310-1311.
70. ZACCARA G, PAGANINI R, CAMPOSTRINI R, ARNELOTI G, ZAPPOLI R, MORONI F. Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur Neurol 1984: 23: 104-112.
71. MIYAZAKI C, MATSUYAMA K, ICHIKAWA M, et al. Effect of sodium valproate (VPA) on cerebral amino acids: mechanism of gamma-aminobutyric acid (GABA) elevation and possible causal relation of VPA-induced encephalopathy and glutamine level. Chem Pharmacol Bull 1988: 36: 3589-3594.
72. STILMAN N, MASDEU JC. Incidence of seizures with phenytoin toxicity. Neurology 1985: 35: 1769-1772.
73. OSORIO I, BURNSTINE TH, REMLER B, MANON-ESPAILLAT R, REED RC. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989: 30: 230-234.
74. RUSSEL MA, BOUSVAROS G. Fatal results from diphenylhydantoin administered intravenously (letter). JAMA 1968: 206: 2118-2119.
75. ZIEGLER DK. Toxicity to the nervous system of diphenylhydantoin: a review. Int J Neurol 1978: 2: 383-400.
76. ZWARTS RJ, SIE O. A case report of phenytoin encephalopathy. Correlation between serum levels, seizure increase and EEG spike and wave activity. Clin Neurol Neurosurg 1985: 87: 205-208.
77. KÖRNER E, LADURNER G, ENGE S, LECHNER H. Hydantoinintoxikation: Klinik, Labor und EEG. Nervenarzt 1983: 54: 548-552.
78. KUSCHKE R, KIRCHNER P. Bericht über einen Fall von Status psychomotoricus mit tonischen Dämmerattacken bei Medikamentenüberdosierung. Psychiatr Neurol Med Psychol Leipzig 1972: 24: 282-288.
79. BRUNI J. Phenytoin. Toxicity. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 345-350.
80. DAM M. Diphenylhydantoin: neurological aspects of toxicity. In: WOODBURY DNM, PENRY JK, SCHMIDT RP, eds. Antiepileptic drugs. New York: Raven Press, 1972: 227-235.
81. GLASER GH. Diphenylhydantoin toxicity. In: WOODBURY DM, PENRY JK, SCHMIDT RR eds. Antiepileptic drugs. New York: Raven Press, 1972: 219-226.
82. KOKENGE R, KUTT H, MCDOWELL F. Neurological sequelae following Dilantin overdose in a patient and in experimental animals. Neurology 1965: 15: 823-829.
83. LASCELLES PT, KOCEN RS, REYNOLDS EH. The distribution of plasma phenytoin levels in epileptic patients. J Neurol Neurosurg Psychiatry 1970: 33: 501-505.
84. BAZEMORE RP, ZUCKERMAN EC. On the problem of diphenylhydantoin induced seizures. Arch Neurol 1974: 31: 243-249.
85. GRUBER CM, HAURY VA, DRAKE ME. The toxic actions of sodium dephenyl hydantoinate (Dilantin) when injected intraperitoneally and intravenously in experimental animals. J Pharmacol Exp Ther 1940: 68: 433-436.
86. PATEL H, CRICHTON JV. The neurologic hazards of diphenylhydantoin in childhood. J Pediatr 1968: 73: 676-684.
87. GRAHAM JA, BACHMAN DS. Seizures associated with phenytoin toxicity. Clin Pharm 1986: 5: 286-287.
88. LLOYD GK, GILLENWATER G. Epilepsy and antiepileptic drugs. In: MUNSON PL, MUELLER RA, BREESE GR, eds. Principles of pharmacology. New York: Chapman & Hall, 1995: 362-398.
89. WEAVER DF, CAMPIELD P, FRASER A. Massive carbamazepine overdose: clinical and pharmacologic observations. Neurology 1988: 38: 755-759.
90. WILKUS RJ, DODRILL CB, TROUPIN AS. Carbamazepine and the electroencephalogram of epileptics: a double blind study in comparison to phenytoin. Epilepsia 1978: 19: 283-291.
91. SHIELDS WD, SASLOW E. Moyclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983: 33: 1487-1489.
92. PRYSE-PHILLIPS WEM, JEAVONS PM. Effect of carbamazepine (tegretol) on the electroencephalograph and ward behaviour of patients with chronic epilepsy. Epilepsia 1970: 11: 263-273.
93. LÖSCHER W, SCHMIDT D. Which animal model should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988: 2: 145-181.
94. SWINYARD EA, WOODWARD JH. Experimental detection, quantification, and evaluation of anticonvulsants. In: WOODBURY DM, PENRY JK, PIPPENGER CE, eds. Antiepileptic drugs. New York: Raven Press, 1982: 111-126.
95. TALWAR D, ARORA MS, SHER PK. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994: 35: 1154-1159.
96. SACHDEO R, CHOKROVERTY S. Enhancement of absence with tegretol. Epilepsia 1985: 26: 534.
97. LIPORACE JD, SPERLING MR, DICHTER MA. Absence seizures and carbamazepine in adults. Epilepsia 1994: 35: 1026-1028.
98. LIU Z, VERGNES M, DEPAULIS A, MARESCAUX C. Involvement of the intrathalamic GABA-B neurotransmission in the control of absence seizures in the rat. Neuroscience 1992: 1: 87-93.
99. HOSFORD DA, CLARK S, CAO Z et al. The role of GABA-B receptor activation in absence seizures of lethargic mice. Science 1992: 257: 398-401.
100. LOUIS S, KUTT H, MCDOWELL F. Intravenous diphenylhydantoin in experimental seizures. II. Effect on penicillin-induced seizures in the cat. Arch Neurol 1968: 18: 472-477.
101. ROSEMAN E. Dilantin toxicity: a clinical and electroencephalographic study. Neurology 1961: 11: 912-922.
102. MILLIGAN N, OXLEY J, RICHENS A. Acute effects of intravenous phenytoin on the frequency of interictal spikes in man. Br J Clin Pharmacol 1983: 16: 285-289.
103. LIU Z, SEILER N, MARESCAUX C, DEAPULIS A, VERGNES M. Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. Eur J Pharmacol 1990: 182: 109-115.
104. DELGADO-ESCUETA AV, WARD AA, WOODBURY DM, PORTER RJ. New ways of research in the epilepsies. Adv Neurol 1986: 44: 21-33.
105. PETERSON GM, RIBAK CE, OERTEL WH. A regional increase in the number of hippocampal GABAergic neurons and terminals in the seizure-sensitive gerbil. Brain Res 1985: 340: 384-389.
106. WENDLAND KL. Myoklonien nach Gaben von Carbamazepin. Nervenarzt 1968: 39: 231-233.
107. DREIFUSS F. Ethosuximide. Toxicity. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 675-679.
108. FINDEIS B. Möglichkeit der Provokation von Grand mal-Serien unter Ethosuximid-Therapie: zwei Fallberichte. Psychiatr Neurol Med Psychol Leipzig 1990: 42: 576-577.
109. DULAC O, PLOUIN P. Infantile spasms and West Syndrome. In: WYLLIE E, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea & Febiger, 1993: 464-491.
110. AMAND G, EVRARD P. Le lorazepam injectable dans les etats de mal epileptique. Rev EEG Neurophysiol Clin 1976: 62: 41-44.
111. DIMARIO FJ JR, CLANCY RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988: 4: 249-251.
112. HOMAN RW, TREIMAN DM. Benzodiazepines. Lorazepam. In: LEVY RH, MATTSON RH, MELDRUM BS (eds) Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 779-790.
113. WALTREGNY A, DARGENT J. Preliminary study of parenteral lorazepam in status epilepticus. Acta Neurol Belg 1975: 75: 219-229.
114. BALLERINI RICCI B, BENEDETTI P, RICCI GF. Electroclinical changes induced by sleep and administration of diazepam in a girl with diffuse epileptogenic encephalopathy and generalized convulsive manifestations. Rev Neurol 1972: 42: 297-303.
115. TASSINARI CA, GASTAUT H, DRAVET C, ROGER JA. Paradoxical effect: status epilepticus induced by benzodiazepines (Valium and Mogadan) (abstract). Electroencephalogr clin Neurophysiol 1971: 31: 182.
116. TASSINARI CA, DRAVET C, ROGER J, CANO JP, GASTAUT H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972: 13: 421-435.
117. BARUZZI A, MICHELUCCI R, TASSINARI CA. Benzo diazepines. Nitrazepam. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 735-749.
118. HALASZ P, VELOK GY, HIDASI J, BOCZAN G. Transitional electroencephalographic manifestations between ictal generalized spike-and-wave pattern and repetitive fast discharge of grand mal type. Acta Med Acad Sci Hung 1968: 25: 161-172.
119. GASTAUT H, COURJON J, POIRE R, WEBER M. Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia 1971: 12: 197-214.
120. SATO S, MALOW BA. Benzodiazepines. Clonazepam. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 725-734.
121. TURNER M, GORMI D, SCHUSTER G, NIN H. A new activation agent in electroencephalography: the propanidid. Preliminary report. Electroencephalogr Clin Neurophysiol 1971: 31: 629.
122. FEUCHT M, BRANTNER-INTHALER S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994: 35: 993-998.
123. SMITH M, JEWKES DA. Other antiepileptic drugs. Chlormethiazole. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 953-962.
124. OTANI K, TAGAWA T, FUTAGI Y, OKAMOTO N, YABUUCHI H. Induced microseizures in West syndrome. Brain Dev 1991: 13: 196-199.
125. OHTAHATRA S, OHTSUKA Y, MIYAKA S et al. Induced microseizures - a clinical and electroencephalograpohic study. Tenkan Kenkyu (Tokyo) 1983: 1: 51-60.
126. OHTSUKA Y, YOSHIDA H, MIYAKE S et al. Induced microseizures: clinical and electroencephalographic study. In: AKIMOTO H, KAZAMATSURI H, SEINO M, WARD A, eds. Advances in Epileptology, XIIIth Epilepsy International Symposium. New York: Raven Press, 1982: 33-35.
127. SANO N, NAGAO H, MORIMOTO T, TAKAHASHI M, HABARA S, MATSUDA H. A case of West syndrome which presented induced microseizures. Rinsho Noha (Osaka) 1984: 26: 541-542.
128. ICHIYAMA T, HAYASHI T, TATEISHI H, TANAKA H. ACTH-induced tonic seizures. The influence of clonazepam on the induction of seizures. Rinsho Noha (Osaka) 1990: 32: 410-412.
129. KANAYAMA M, ISHIKAWA T, TAUCHI A, et al. ACTH-induced seizures in an infant with West syndrome. Brain Dev (Tokyo) 1989: 11: 329-331.
130. URAMOTO K, TOMIMOTO M, HARA H, et al. Clinical study of intractable epilepsy cases aggravated by ACTH therapy. Brain Dev (Tokyo) 1980: 2: 265.
131. CHIRON C, DULAC O. Controlled trials in West Syndrome. In: FEJERMAN N, CHAMOLES NA, eds. New trends in pediatric neurology. Amsterdam: Elsevier, 1993: 269-273.
132. TAUBØLL E, LUNDERVOLD A, GJERSTAD L. Temporal distribution of seizures in epilepsy. Epilepsy Res 1991: 8: 153-165.
133. BINNIE CD, AARTS JHP, HOUTKOOPER MA, LAXMINARAYAN R, MARTINS DA SILVA A, MEINARDI H, NEGELKERKE N, OVERWEG J. Temporal characteristics of seizures and epileptiform discharges. Electroencephalogr Clin Neurophysiol 1984: 58: 498-505.
134. MILTON JG, GOTMAN J, REMILLARD GM, ANDERMAN F. Timing of seizure recurrence in adult epileptic patients: a statistical analysis. Epilepsia 1987: 28: 471-478.
135. BAUER J, GHANE Y, FLÜGEL D, WILDT L, STEFAN H. Ursachen, Verlauf und Therapie von Anfallsclustern bei Temporallappenepilepsien und katamenialen epileptischen Anfällen. Schweiz Archiv Neurol Psychiatr 1992: 143: 17-134.
136. MCDONALD RL. Carbamazepine: mechanisms of action. In: LEVY RH, MATTSON RH, MELDRUM BS, eds. Antiepileptic drugs, 4th edition. New York: Raven Press 1995: 491-498.
137. GALE K. GABA and epilepsy: basic concepts from preclinical research. Epilepsia 1992: 33(Suppl 5): S3-S12.
138. BOURGEOIS BFD. Combination drug therapy (monotherapy versus polytherapy). In: DODSON WE, PELLOCK JM, eds. Pediatric epilepsy: diagnosis and therapy. New York: Demos Publ., 1992: 367-371.
139. HANSON RA, MENKES JA. A new anticonvulsant in the management of minor motor seizures. Dev Med Child Neurol 1972: 14: 3-14.
140. SCHMIDT D. Reduction of two drug therapy in intractable epilepsy. Epilepsia 1983: 24: 368-376.
141. THEODORE WH, PORTER RJ. Removal of sedative-hypnotic antiepileptic drugs from the regimens of patients with intractable epilepsy. Ann Neurol 1983: 13: 368-376.
142. AICARDIE J. Clinical approach to the management of intractable epilepsy. Dev Med Child Neurol 1988: 30: 429-440.
143. TAYLOR DC, MCKINLAY I. When not to treat epilepsy with drugs. Dev Med Child Neurol 1984: 26: 822-833.
144. MERRITT HH, PUTNAM TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 1938: 39: 1003-1025.
145. GRUBER CM, HARRY VG, DRAKE ME. The toxic actions of sodium diphenylhydantoinate (Dilantin) when injected peritoneally and intravenously in experimental animals. J Pharmacol Exp Ther 1940: 68: 433-436.
146. HURST DL. Carbamazepine induced absence and minor motor seizures. Neurology 1985: 35: 286.